Amarin (AMRN)
(Delayed Data from NSDQ)
$0.55 USD
+0.02 (4.52%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $0.55 0.00 (0.26%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
AMRN 0.55 +0.02(4.52%)
Will AMRN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRN
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
Other News for AMRN
Amarin (AMRN) Stock Surges Amid Mixed Industry Performance
Top 3 Health Care Stocks You'll Regret Missing In Q4
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)
Amarin announces to present additional analysis from REDUCE-IT outcomes trial
Amarin announces to present additional analysis from REDUCE-IT outcomes trial